Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06346899
Other study ID # TAK-743-4012
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date August 14, 2024
Est. completion date August 13, 2025

Study information

Verified date May 2024
Source Takeda
Contact Takeda Contact
Phone +1-877-825-3327
Email medinfoUS@takeda.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The Chinese health authority has approved lanadelumab to prevent Hereditary Angioedema (HAE) attacks in persons of 12 years and older. It has also approved icatibant to treat acute HAE attacks in persons 2 years and older. One of the main aims of this study is to learn about the number of HAE attacks in 1 month in Chinese persons with HAE during their treatment with lanadelumab. The other main aim is to learn how much time is needed to resolve acute HAE attacks when treated with icatibant. Other aims of this study are to learn more about side effects of lanadelumab and icatibant treatment as well as to collect additional information on the treatment with lanadelumab, such as the dose and how often it needs to be given, reasons for stopping the treatment with lanadelumab and how long it was taken until stopping. Participants will be treated by their doctors according to routine medical practice. Only data already available in the medical records of the participants will be reviewed and collected during this study.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 130
Est. completion date August 13, 2025
Est. primary completion date August 13, 2025
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion criteria: - Chinese participants who have received at least one dose of lanadelumab or icatibant from the lanadelumab NMPA approval date (02-Dec-2020) to the date of the day before the 1st site initiation date. - Informed consent will be obtained from the participant (and/or a legally authorized representative) prior to including that participant as a study participant and accessing that participant's data, except for cases in which the informed consent can be waived by the site. Exclusion criteria: • Participation in other interventional studies involving lanadelumab, icatibant, or any other HAE drug or investigational product on or after the date of the participant's lanadelumab or icatibant initiation.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
No intervention
This is a non-interventional study.

Locations

Country Name City State
China West China Hospital of Sichuan University Chengdu Sichuan
China The First Affiliated Hospital of Fujian Medical University Fuzhou Fujan
China The First Affiliated Hospital ,Sun Yat-sen University Guangzhou Guangdong
China The Second Affiliated Hospital of Guangzhou Medical University Guangzhou Guangdong
China The Second Affiliated hospital Zhejiang University School of Medicine Hangzhou Zhejiang
China Shandong Provincial Hospital Affiliated to Shandong First Medical University Jinan Shandong
China First Affiliated hospital of Kunming Medical University Kunming Yunnan
China Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine Shanghai Shanghai
China The First Hospital of China Medical University Shenyang Liaoning
China Shanxi Bethune hospital Taiyuan Shanxi
China Tongji Hospital,Tongji Medical College,Huazhong University of Science & Technology Wuhan Hubei
China The Second Affiliated hospital of Xian Jiaotong University Xian Shanxi

Sponsors (1)

Lead Sponsor Collaborator
Takeda

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Monthly Rate of HAE Attacks for Each Lanadelumab-treated Participant During the Lanadelumab Exposure Period The HAE monthly attack rate is defined as the total number of attacks that occurred when the participant was in a lanadelumab exposure period, divided by the total lanadelumab exposure time (in days), multiplied by 28 days. From the first dose of study drug up to approximately 3 years 8 months
Primary Median Time to Complete Attack Resolution for Icatibant Treated Participants Time to complete attack resolution among icatibant-treated participants during the retrospective observation period is defined as the time between icatibant first injection and the earliest time of complete resolution of symptoms for each attack during the retrospective observation period that was treated with icatibant. From the first dose of study drug up to approximately 3 years 8 months
Secondary Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) During Lanadelumab and Icatibant Exposure Period An AE is any untoward medical occurrence in a participant administered a studied drug and which does not necessarily have to have a causal relationship with the studied drug. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, a new disease or worsening in severity or frequency of a concomitant disease, temporally associated with the use of a studied drug, whether or not the event is considered causally related to the use of the product. An SAE is any untoward medical occurrence that at any dose: results in death, life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent, significant disability/incapacity, a congenital abnormality/birth defect, an important medical event in the opinion of the healthcare provider, may jeopardize the participant or may require intervention to prevent one of the other outcomes listed in the definition above. From the first dose of study drug up to approximately 3 years 8 months
Secondary Dosage of Lanadelumab Among Lanadelumab-treated Participant During the Lanadelumab Exposure Period Dosage of lanadelumab used during the lanadelumab exposure period will be assessed. From the first dose of study drug up to approximately 3 years 8 months
Secondary Frequency Administration of Lanadelumab Among Lanadelumab-treated Participant During the Lanadelumab Exposure Period Frequency administration of lanadelumab among lanadelumab-treated participant during the lanadelumab exposure period will be assessed. From the first dose of study drug up to approximately 3 years 8 months
Secondary Number of Participants with Reasons of Discontinuation of Lanadelumab During the Lanadelumab Exposure Period Number of participants with reasons of discontinuation of lanadelumab during the lanadelumab exposure period will be assessed. From the first dose of study drug up to approximately 3 years 8 months
Secondary Time to Lanadelumab Discontinuation Among Lanadelumab-treated Participant During the Lanadelumab Exposure Period The time to lanadelumab discontinuation is defined as the time from lanadelumab initiation to the first lanadelumab discontinuation. From the first dose of study drug up to approximately 3 years 8 months
See also
  Status Clinical Trial Phase
Completed NCT02865720 - Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE) Phase 3
Completed NCT04861090 - A Study in Teenagers and Adults With Hereditary Angioedema (HAE) Type I or Type II Who Use Lanadelumab as Long-Term Prophylaxis
Recruiting NCT05489640 - A Study in Adults With Hereditary Angioedema (HAE) Who Currently Receive Icatibant at Home
Completed NCT02584959 - Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema Phase 3
Completed NCT01826916 - EDEMA2: Evaluation of DX-88's Effect in Mitigating Angioedema Phase 2
Completed NCT04057131 - FIRAZYR General Drug Use-Results Survey (Japan)
Recruiting NCT05819775 - CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema Phase 3
Recruiting NCT05397431 - A Survey of Lanadelumab in Participants With Hereditary Angioedema
Completed NCT02741596 - Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE Phase 3
Completed NCT02093923 - A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants Phase 1
Completed NCT01541423 - A European Post-Authorisation Observational Study Of Patients With Hereditary Angioedema
Completed NCT03845400 - A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America
Completed NCT02586805 - Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE Phase 3
Completed NCT02052141 - Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema Phase 3
Completed NCT03888755 - A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Participants Phase 3
Recruiting NCT05147181 - A Study With Lanadelumab in Persons With Hereditary Angioedema (HAE) in Poland
Recruiting NCT05469789 - A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE)
Completed NCT05460325 - A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE) Phase 3
Completed NCT01095510 - CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12 Phase 2
Recruiting NCT05578417 - A Study to Review the Treatment and Outcomes of Teenagers and Adults With Non-histaminergic Angioedema With Normal C1 Inhibitor in Canada